Long-Term Efficacy And Safety Profile Of The Anti-TNF Golimumab Confirmed

MSD have announced that five-year data from pivotal Phase 3 clinical studies demonstrate that once-monthly, subcutaneous (SC) injections of Simponi� (golimumab) provided sustained improvements in the signs and symptoms of patients with both active ankylosing spondylitis (AS) and moderate to severe, active rheumatoid arthritis (RA) over five years.1, 2 The new findings from long-term extensions of the GO-FORWARD and GO-RAISE clinical studies were presented at the 2013 European League Against Rheumatism (EULAR) Annual Congress...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/9RUGma5hQiU/261865.php

medical rehab sport